Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO Sells $21,421.40 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 715 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $29.96, for a total transaction of $21,421.40. Following the sale, the chief accounting officer now owns 36,643 shares in the company, valued at approximately $1,097,824.28. This trade represents a 1.91 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

James George Chopas also recently made the following trade(s):

• On Wednesday, January 22nd, James George Chopas sold 1,096 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.43, for a total value of $33,351.28.
• On Monday, January 13th, James George Chopas sold 783 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total value of $22,472.10.

Apellis Pharmaceuticals Trading Up 1.2 %

NASDAQ APLS opened at $30.76 on Friday. The stock has a market cap of $3.83 billion, a P/E ratio of -15.15 and a beta of 0.94. The company’s fifty day simple moving average is $31.95 and its 200-day simple moving average is $33.25. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. During the same quarter in the prior year, the firm earned ($1.17) EPS. The business’s quarterly revenue was up 78.3% compared to the same quarter last year. Equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on APLS. Wells Fargo & Company lowered their price target on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Morgan Stanley initiated coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price target for the company. Piper Sandler decreased their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. Bank of America dropped their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, William Blair started coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They issued an “outperform” rating on the stock. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Envestnet Asset Management Inc. boosted its stake in shares of Apellis Pharmaceuticals by 42.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after buying an additional 39,931 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Apellis Pharmaceuticals by 23.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after acquiring an additional 735,160 shares in the last quarter. Profund Advisors LLC increased its position in shares of Apellis Pharmaceuticals by 90.7% in the 2nd quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock worth $1,648,000 after purchasing an additional 20,435 shares during the last quarter. Algert Global LLC raised its stake in shares of Apellis Pharmaceuticals by 137.8% in the 2nd quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after purchasing an additional 71,650 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new position in Apellis Pharmaceuticals in the third quarter worth about $1,370,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).